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Abstract
Background: In 2015, Portugal was the OECD country with the highest reported consumption of BZD. Physician’s
perceptions and attitudes regarding BZD are main determinants of related prescription habits. This study aimed to
characterize beliefs and attitudes of Portuguese physicians regarding the prescription, management challenges,
benefits, risks and withdrawal effects of BZD.
Methods: A cross-sectional, observational study with online data collection through anonymous self-administered
questionnaire. Physicians registered with the Portuguese Medical Association were invited to participate through
direct e-mail message. Physicians were asked to give their opinion (using a 5-points Likert scale) regarding the
prescription of BZD, their benefits and risks in the management of insomnia and anxiety, the possible adverse
effects of chronic use and alternative non-pharmacologic approaches. Descriptive statistics were used and groups
were compared through logistic regression.
Results: A total of 329 physicians participated in the study (56% family physicians). Mean age was 44.10 ± 15.2
years, with 19.03 ± 14.9 years of clinical experience. Fifty eight percent of participants were female. Physicians
reported BZD’s negative impact on cognitive function (89%), association with road traffic accidents (88%) and falls
(79%). Also, 58% shared the belief that chronic use is justified if the patient feels better and without adverse events.
Although 68% reported to feel capable of helping patients to reduce or stop BZD, 55% recognized difficulties in
motivating them. Compared to other medical specialists (altogether), family physicians were significantly more
aware about the adverse effects of BZD and considered that chronic use may not be justified. Conversely, more
family physicians expressed concerns about their skills to motivate patients engaging in withdrawal programs and
to support them during the process.
Conclusion: Our results show that physicians’ awareness about risks of BZD chronic use is adequate though their
attitudes and self-perceived skills towards promoting BZD withdrawal can be improved. Interventions in primary
care are needed to capacitate physicians to better motivate patients for BZD withdrawal.
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Background
Benzodiazepines (BZD) were introduced in clinical prac-
tice as anxiolytic agents in the early 60s [1]. This class of
drugs is used in the treatment of anxiety and sleep disor-
ders, among other conditions for which their effectiveness
is well established [2, 3]. Although BZD are approved for
short-term treatment, its long-term use is common and
recognized as a relevant public health problem [4, 5].
In the United States, a study reported that approxi-
mately 5.2% of adults (18–80 years) used BZD, and that
the long-term consumption increased with age, from
14.7% (18–35 years) to 31.4% (65–80 years) [6]. Another
study in British Columbia showed that between 1996 and
2006, the use of BZD increased from 7.8 to 8.4%, with
3.5% corresponding to long-term use in 2006 [7]. In
Europe, the consumption of BZD is even higher. In Spain,
BZD consumption has undergone continued growth since
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2000, from a DHD (Defined Daily Dose per 1000 persons)
of 56.7 to a DHD of 89.3 in 2012 [8, 9]. In Portugal, the
consumption of BZD was 96 DHD in 2012, 6% more than
in 2000 [10]. Compared with other European countries,
Portugal is the OECD country with the highest reported
consumption of BZD, with 114 DHD in 2015 versus 87
DHD in Spain and 16 DHD in the United Kingdom [11].
The BZD long-term use has been discouraged due to
risks of dependence and negative impact on psychomotor
abilities, particularly in older patients, with increased risk of
falls and fractures [12] as well as road-traffic accidents [13].
More recently, BZD long-term use has been associated with
cognitive deficits and dementia syndromes [14–17]. Hence,
it is important to implement prevention programs for in-
appropriate BZD use and to motivate patients with chronic
consumption to participate in supervised programs of BZD
discontinuation [2, 18, 19].
Several studies regarding BZD prescription have
shown that the decision to prescribe and maintain the
BZD is complex and affected by several factors [20–23],
including physicians’ knowledge, beliefs and attitudes
regarding benefits and risks of BZD [24]. In fact, even
though guidelines recommend that non-pharmacological
interventions should be used as a first-line treatment for
anxiety [25] and sleep disorders [26], the prescription of
BZD may be perceived by medical doctors as an easier
and more accessible way to address these health conditions
[24], particularly in the primary healthcare setting. Indeed,
though other medical specialists often decide BZD initi-
ation, family physicians are the main prescribers in the
long-term use [27, 28]. The limited consultation time per
patient, the patients’ pressure for prescription refill and the
perceived low risks and high effectiveness of BZD [24, 29]
may influence whether or not to initiate, continue or
terminate the prescription of BZD.
This study aimed to characterize beliefs and attitudes
of Portuguese physicians regarding prescription, con-
sumption and withdrawal of BZD. This is part of a
broader project that evaluated the feasibility and effect-
iveness of a clinical protocol for BZD discontinuation at
primary health care level.
Methods
Study design
A cross-sectional study was conducted with data col-
lected from December 2015 to February 2016, among
physicians registered with the Portuguese Medical
Association (PMA). The study was approved by the
Regional Health Administrations’ Ethics Committee
and authorized by the Portuguese Data Protection Au-
thority. Data were collected through Google Forms®
and compiled into a protected database, only access-
ible to the research team.
Instrument and procedure
An anonymous self-administered online questionnaire was
developed for this study. The initial version of the ques-
tionnaire was developed taking into consideration results
of qualitative studies investigating dimensions and factors
related with BZD prescribing and usage [20–24, 29]. The
questionnaire comprises four different sections: i) general
beliefs about BZD, mainly about risks and benefits, ii)
attitudes about prescription and chronic use of BZD, iii)
self-perception of literacy about BZD and iv) self-efficacy
perception for promoting withdrawal.
The questionnaire’s validation procedure consisted in
discussions between the research team and two external
experts on the relevance of the selected dimensions and
factors (content validity). Additionally, six physicians of
different specialties were invited to respond to the ques-
tionnaire to test general comprehension and consistency.
The final version of the questionnaire was named Per-
ception about Use of BZD Scale (PUBS) and included 30
items (see Table 3). Respondents expressed their agree-
ment with each of the statements through a 5-point Likert
scale that ranged from “1-Strongly disagree” to “5-Strongly
agree”. Physicians from all Specialist Colleges were invited
to participate through direct e-mail, sent by the PMA.
The email message included a brief information about the
study and a link that landed in a webpage with more infor-
mation about the participation procedure and goals. Phy-
sicians had access to the questionnaire after agreeing with
the participation terms (by clicking on a “I agree” box). A
reminder was sent by e-mail 1 month after the first mes-
sage. Because answers were anonymous, the reminder was
sent to the complete list of physicians, and it was re-
quested to those that had participated in the first round to
skip the invitation.
Statistical analysis
Data were exported to and analyzed with IBM® SPSS®
(version 22.0). Exploratory factor analysis was performed
to study the structure of the questionnaire. The principal
components extraction method with Varimax rotation
was used. Each item was allocated to a factor when
having a loading of 0.4 or higher. Sampling adequacy
was tested with Kaiser–Meyer–Olkin (KMO) measure
and sphericity was tested with Bartlett’s test. Cronbach’s
alpha was used to assess the internal reliability of the
complete set of items as well as for each dimension that
emerged from the factor analysis.
The preliminary psychometric properties’ analysis fully
supported the PUBS initial structure of four dimensions
[30]. 1) Doctors’ beliefs about BZD (items: 1, 2, 3, 4, 5, 6, 7,
8, 9, 10 e 11; alpha coefficient = 0.84); 2) Doctors’ attitudes
about BZD prescription (items: 13, 14, 15, 16, 17, 18, 19,
22, 23, 24, 26, 27, 30; alpha coefficient = 0.65); 3) Doctors’
self-perception of literacy about BZD (items: 12, 21, 25;
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alpha coefficient = 0.60); 4) Doctors’ self-efficacy per-
ception for promoting withdrawal (items: 20, 28, 29;
alpha coefficient = 0.41). The overall alpha coefficient
of PUBS was 0.78.
The sample was compared with the population of physi-
cians registered with the PMA regarding main sociodemo-
graphic variables and distribution by medical specialties.
The data regarding the number of physicians registered
with PMA was obtained through the official PMA website
(www.ordemdosmedicos.pt).
Univariate descriptive analysis was conducted to de-
scribe PUBS items. Total score of the scale, as well as
scores for each dimension, were computed as a linear
sum. Logistic regression test was used for studying the as-
sociation between type of medical specialty (family physi-
cians versus other medical specialists, due to the small
sample size of these other specialties) and agreement with
each item. Comparisons of PUBS mean scores by type of
medical specialty were done through Student’s t test for
independent samples.
Results
A total of 329 physicians, including 56% family physi-
cians, participated in the study. The mean age was 44.1
± 15.2 years, with 19.0 ± 14.9 years of clinical experience.
Fifty eight percent of participants were female (Table 1).
Regarding their clinical practice, 36% of the respondents
worked mainly at a hospital. Regarding the category
“other medical specialists”, 6% of respondents were psy-
chiatrists with 20.4 ± 15.2 years of clinical experience
and 5% were internists, with 17.4 ± 14.4 years of clinical
experience.
Table 2 presents the answers to the PUBS question-
naire. Regarding beliefs about BZD, 30% of physicians
considered that patients get a high-quality sleep with
BZD, with significant differences between family physi-
cians and other specialists. Most respondents were
aware of BZD negative impact on cognitive function
(89%) and about BZD association with road traffic acci-
dents (88%) and falls (79%). Compared to other physi-
cians, family physicians were significantly more aware of
BZD impact on cognitive function (OR = 4.75), of BZD
association with falls (OR = 5.48) and of increased risk of
road traffic accidents (OR = 2.49).
When considering attitudes towards BZD prescription,
42% of respondents disagreed with the statement that
chronic use is justified if the patient feels better with no
observed side effects. Although 68% felt capable of helping
patients to reduce/stop benzodiazepines, 55% recognized
difficulties in motivating them. Half of the physicians (51%)
agreed that they feel pressured by patients to prescribe
BZD. Compared to other physicians, family physicians
have higher odds in believing that patients feel they are not
being taken seriously if the BZD are not prescribed, and
that they might be compromising the patient-doctor rela-
tionship when not fulfilling such expectation.
Regarding the four dimensions of the PUBS, significant
differences were found between family physicians and
other medical specialists (Table 3). Family physicians
had less positive beliefs regarding BZD and less positive
Table 1 Characteristics of the respondents





Female 116 (63.0%) 74 (51.0%) 0.03a) 152 (57.7%)
Male 68 (37.0%) 71 (49.0%) 207 (42.3%)
Age group, n (%)*
≤ 35 years 101 (55.2%) 50 (34.5%) < 0.001a) 159 (44.4%)
36–55 years 27 (14.8%) 43 (29.7%) 81 (22.6%)
≥ 56 years 55 (30.1%) 52 (35.9%) 118 (33.0%)
Age, mean ± sd* 41.5 ± 14.3 46.7 ± 15.9 0.002b) 44.1 ± 15.2
Years of clinical practice, mean ± sd 16.2 ± 14.1 22.0 ± 15.5 < 0.001b) 19.0 ± 15.0
Nr of patient with prescribed BZD for the first time (last 3 months)
No patients 31 (16.8%) 41 (28.3%) < 0.001a) 76 (21.2%)
Between 1 and 5 patients 121 (65.8%) 55 (37.9%) 192 (53.5%)
Between 6 and 10 patients 20 (10.9%) 17 (11.7%) 39 (10.9%)
More than 10 patients 5 (2.7%) 16 (11.0%) 25 (7.0%)
Not applicable 7 (3.8%) 16 (11.0%) 27 (7.5%)
a) Chi-square test for independence
b) Student’s t test for independent samples
*One missing value for variable Age (n = 183)
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Table 2 Responses to PUBS item: comparison between family physicians and other specialists
Items Family physicians (n = 184) Other specialists (n = 145) OR for agreement
(95% CI)c)n (%) Agreementa Disagreementb Agreementa Disagreementb
Doctors’ beliefs about BZD
1. With BZD, the patient gets a high-quality sleep 44 (23.9%) 94 (51.1%) 55 (37.9%) 57 (39.3%) 1.94** (1.21–3.13)
2. With BZD, the patient does not wake up so many
times during night
115 (62.5%) 28 (15.2%) 93 (64.1%) 33 (22.8%) 1.07 (0.68–1.69)
3. With BZD, the patient feels more rested when
waking up in the morning
50 (27.2%) 73 (39.7%) 39 (26.9%) 54 (37.2%) 0.99 (0.60–1.61)
4. With BZD, the patient feels less angry 99 (53.8%) 32 (17.4%) 96 (66.2%) 23 (15.9%) 1.68 * (1.07–2.64)
5. Chronic use of BZD does not represent a health risk
to the patient
7 (3.8%) 170 (92.4%) 11 (7.6%) 119 (82.1%) 2.08 (0.78–5.49)
6. Chronic use of BZD contributes to the patients’ well-being 41 (22.3%) 81 (44%) 48 (33.1%) 48 (33.1%) 1.73* (1.06–2.82)
7. Chronic use of BZD is essential to patients’ anxiety control 51 (27.7%) 85 (46.2%) 48 (33.1%) 67 (46.2%) 1.29 (0.80–2.07)
8. Chronic use of BZD is a public health problem 157 (85.3%) 12 (6.5%) 113 (77.9%) 14 (9.7%) 1.62 (0.72–3.64)
9. Chronic use of BZD enhances the risk of several falls 161 (87.5%) 6 (3.3%) 98 (67.6%) 20 (13.8%) 5.48** (2.13–14.10)
10. Chronic use of BZD may impair cognitive performance 174 (94.6%) 4 (2.2%) 119 (82.1%) 13 (9%) 4.75** (1.51–14.92)
11. Chronic use of BZD increases the risk of road
traffic accidents
168 (91.3%) 5 (2.7%) 121 (83.4%) 9 (6.2%) 2.49* (0.82–7.64)
Doctors’ attitudes about BZD prescription
13. BZD consumption in unnecessary in most cases 121 (65.8%) 24 (13%) 83 (57.2%) 25 (17.2%) 1.52 (0.81–2.84)
14. It is important to inform the patient about the risk of
tolerance associated with BZD
181 (98.4%) 1 (0.5%) 138 (95.2%) 1 (0.7%) 1.31 (0.08–21.16)
15. It is important to inform the patient about the risk of
addiction associated with BZD
183 (99.5%) – 138 (95.2%) 4 (2.8%) 0.10 (0.01–0.89)
16. Chronic use of BZD is justified if the patient feels
better and without side effects
47 (25.5%) 94 (51.1%) 71 (49.0%) 44 (30.3%) 2.79** (1.76–4.45)
17. I feel pressured by patients to prescribe BZD 125 (67.9%) 33 (17.9%) 44 (30.3%) 74 (51%) 6.37** (3.73–10.88)
18. Patients feel like they are not taken seriously
when I don’t prescribe BZD
49 (26.6%) 83 (45.1%) 20 (13.8%) 90 (62.1%) 2.66** (1.46–4.84)
19. When I refuse to prescribe BZD, I’m challenging
the patient-doctor relationship
37 (20.1%) 98 (53.3%) 7 (4.8%) 109 (75.2%) 5.88** (2.51–13.79)
22. There is an acceptable level of anxiety and the
doctor should help people to deal with it
173 (94.0%) 3 (1.6%) 140 (96.6%) 2 (1.4%) 0.82 (0.14–4.99)
23. The easiest way to deal with a patients’ anxiety
is to prescribe a BZD
44 (23.9%) 123 (66.8%) 28 (19.3%) 106 (73.1%) 0.76 (0.45–1.29)
24. Prescribing BZD in clinical cases of anxiety is the
most appropriate way to deal with those cases
14 (7.6%) 119 (64.7%) 16 (11.0%) 91 (62.8%) 1.51 (0.71–3.19)
26. Non-pharmacological approaches for anxiety
need to be complemented with medication
39 (21.2%) 63 (34.2%) 32 (22.1%) 52 (35.9%) 1.05 (0.62–1.79)
27. Non-pharmacological approaches for sleep disorders
need to be complemented with medication
39 (21.2%) 80 (43.5%) 39 (26.9%) 49 (33.8%) 1.37 (0.82–2.28)
30. Non-pharmacological approaches are appropriate
for most patients
94 (51.1%) 45 (24.5%) 59 (40.7%) 37 (25.5%) 1.31 (0.76–2.26)
Doctors’ self-perception of literacy about BZD
12. I consider myself well informed about the benefits
and risks of BZD
161 (87.5%) 5 (2.7%) 94 (64.8%) 21 (14.5%) 0.26** (0.15–0.46)
21. I don’t feel capable of helping patients to stop/
reduce the BZD consumption
19 (10.3%) 136 (73.9%) 21(14.5%) 90 (62.1%) 0.60 (0.31–1.18)
25. My knowledge on non-pharmacological
approaches is enough to help patient not
to choose for BZD
68 (37.0%) 64 (34.8%) 46 (31.7%) 61 (42.1%) 0.79 (0.50–1.27)
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attitudes towards BZD prescribing (p < 0.001). On the other
hand, family physicians’ self-perception of literacy about
BZD was significantly higher (p = 0.004), except when com-
pared with psychiatrists (M= 3.58 versus M= 4.10).
Discussion
This study aimed to characterize beliefs and attitudes of
the Portuguese physicians regarding BZD prescription,
consumption and withdrawal. A self-administered online
scale was specifically developed for this purpose, the
PUBS, with good psychometric properties when applied
to medical doctors from different specialties (alpha coef-
ficient of 0.78). The coefficient for some of the compo-
nents of the scale (namely the one about Doctors’
perception of self-efficacy for promoting withdrawal) are
rather low, which is expected due to the low number of
items [31]. In any case, the items included in each di-
mension make sense from a conceptual point of view.
We observed that most physicians were aware of
BZD negative impact on cognitive function and their
association with falls and fractures and with road-traffic
accidents. The scarcity of recent studies investigating
physicians’ beliefs and attitudes towards BZD prescrip-
tion makes difficult the external validation of our re-
sults [32]. Some older studies appear to show less
negative attitudes regarding BZD prescription [21, 33].
Risk awareness was higher among family physicians for
each of these types of adverse effects, as compared with
other specialists (OR = 4.75, 5.48 and 2.49 respectively).
Family physicians’ self-perception of literacy regarding
BZD was also significantly higher when compared to
other medical specialists (p = 0.004). Family physicians
considered themselves well informed about benefits
and risks of BZD (88%). However, regarding self-
efficacy for promoting withdrawal, there were still 26%
that didn’t feel capable to motivate patients to stop or
reduce BZD consumption. Hence, being aware of the
risks of BZD chronic use seems to be not enough to
capacitate physicians in motivating patients to cease
consumption. In fact, a systematic review published in
2013, that included studies conducted in Europe,
United Sates, Australia and New Zealand, revealed that
family physicians report challenges in helping patients
to withdraw from BZD [29]. Since family physicians are
usually responsible for prescription refills, the aware-
ness about BZD risks shown in our study may promote
and facilitate interventions aimed at reducing its in-
appropriate and chronic use.
Some studies have reported that physicians may feel am-
bivalent about the decision to prescribe and maintain the
BZD consumption [21, 23, 29]. Concepts such as i) the
role of health professionals in BZD prescription; ii) their
perception about patients’ expectations in receiving a pre-
scription during the appointment; iii) the desire to main-
tain good doctor-patient relationship; iv) and the difficulty
in motivating the patient to accept non-pharmacological
Table 2 Responses to PUBS item: comparison between family physicians and other specialists (Continued)
Items Family physicians (n = 184) Other specialists (n = 145) OR for agreement
(95% CI)c)n (%) Agreementa Disagreementb Agreementa Disagreementb
Doctors’ self-efficacy perception for promoting withdrawal
20. I have difficulties in motivating patients to stop
BZDs’ consumption
114 (62.0%) 48 (26.1%) 66 (45.5%) 40 (27.6%) 1.44** (0.86–2.42)
28. Psychological treatment of anxiety is of difficult access 147 (79.9%) 27 (14.7%) 104 (71.7%) 22 (15.2%) 0.64 (0.38–1.06)
29. It is difficult to motivate patients to see a psychologist 119 (64.7%) 38 (20.7%) 81 (55.9%) 36 (24.8%) 0.69 (0.44–1.08)
* Statistically significant (p-value < .05); ** Highly statistically significant (p-value < .01)
a) Percentage of agreement (answers 4 and 5) b) Percentage of disagreement (answers 1 and 2). c) reference category: family physicians
Neutral point (answer 3 - neither agree or disagree) is not included in the table but was considered for the OR estimation
Table 3 PUBS scores by medical specialty
Family physicians Other medical specialists Total p-valuea
Doctors’ beliefs about BZD Mean (1 to 5 Likert scale) 2.35 2.61 2.47 < 0.001*
Std. deviation 0.04 0.05 0.56
Doctors’ attitudes about BZD prescription Mean (1 to 5 Likert scale) 2.40 2.66 2.52 < 0.001*
Std. deviation 0.03 0.03 0.38
Doctors’ self-perception of literacy about BZD Mean (1 to 5 Likert scale) 3.58 3.37 3.47 0.004*
Std. deviation 0.04 0.06 0.67
Doctors’ perception of self-efficacy for
promoting withdrawal
Mean (1 to 5 Likert scale) 3.35 3.30 3.33 0.440
Std. deviation 0.04 0.05 0.57
* Statistically significant (p-value < 0.05)
a) Student’s t test for independent samples (comparisons of mean PUBS scores by type of medical speciality)
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interventions, all these are central in BZD inappropriate
prescribing decision [24, 27, 29, 34]. Our results are also
consistent with these concepts, since we observed that
family physicians have higher odds in believing that pa-
tients feel they are not being taken seriously when the
physician refuses a BZD prescription refill, and that this
might compromise the doctor-patient relationship. Also,
half of the physicians (51%) reported that they feel pres-
sured by patients to prescribe BZD and 55% recognized
difficulties in motivation them to withdraw BZD. The
long-term use of these drugs may also be influenced by
other aspects such as: i) patients’ lack of knowledge about
the risks and benefits of BZD [21]; ii) patients’ social or
financial problems; iii) the medicalization phenomenon
of human suffering and iv) shortage of timely available
services of psychological counselling and brief psycho-
therapeutic interventions [27, 35, 36]. Furthermore,
several studies support the hypothesis that BZD proper
use depends on the information provided to patients by
the prescriber [22, 24, 29].
Difficulties felt by family physicians could be explained
by lack of training on how to manage beliefs, motiva-
tions and expectations of BZD chronic users, as well as
lack of training for managing the BZD discontinuation
from a pharmacological perspective. Though recommen-
dations exist on the cautious prescription and utilization
of BZD in the treatment of anxiety and insomnia, there
are no formal guidelines in Portugal on how to proceed
to help patients cease or reduce BZD consumption.
Therefore, we believe that there is a need to develop
and validate a clinical protocol to support physicians
and patients in the process of BZD withdrawal at Pri-
mary Care level. In addition, family physicians should re-
ceive adequate training in motivational competencies, in
order to facilitate the patients’ adherence to the discon-
tinuation program. Integrating motivational interview
principles [37] with discontinuation programs may be a
strategic and effective way-to-go, for handling resistant
or ambivalent patients regarding BZD’s withdrawal [38].
Regarding factors influencing initiation and mainten-
ance of BZD chronic use, 68% of family physicians consid-
ered themselves to be pressured by patients to prescribe
BZD. This result is consistent with a study conducted by
Anthierens and colleagues [21] in which family physicians
reported that they were cautious in initiating BZD
usage, but at the same time, felt overwhelmed by the
psychosocial problems of their patients. This difficulty
in dealing with patient’s complaints of anxiety and
insomnia and the few available non-pharmacological
alternatives at a short-term period, can easily lead to
BZD over-prescription.
Some study limitations should be acknowledged. A total
of 329 physicians responded to the questionnaire, which is
a rather good sample. However an accurate calculation of
the response rate was not possible. Even though it is
known how many physicians are members of the Portu-
guese Medical Association, it was not possible to know
how many of them actually received the online invitation
to participate in the study. The percentage of physicians in
our sample with 35 years or younger is 44.4%, which is
lower than what is known for the population registered
with the PMA [39]. Also, the use of an online approach
could represent a bias towards younger physicians who
are most prone to use the e-mail on a regular basis.
A reminder was sent 1 month after the initial e-mail
message to increase the response rate. To ensure question-
naire anonymity, the reminder was sent to the complete
list of physicians, requesting those that had partici-
pated in the first round to skip the invitation. How-
ever, the possibility of duplicate responses cannot be
excluded with certainty.
It should be noted that this questionnaire was intended
for all medical specialists. However, family physicians were
the most represented specialists in the study. This may in-
dicate that family physicians are more aware of the rele-
vance of BZD utilization and consumption, since they are
responsible for most BZD prescription refills.
Further studies to clarify the possible association
between physicians and patients believes and attitudes
towards BZD and the chronic use of these drugs are
warranted.
Conclusion
Our study showed that, in Portugal, physicians are aware
of the risks of BZD chronic use. Family physicians seem to
have significantly less positive beliefs and attitudes to-
wards BZD’s prescription when compared with other
specialists. They also have a better self-perception of liter-
acy about BZD, although expressing concerns about their
skills to help patients with BZD withdrawal. The results of
this study represent a significant contribution to a better
understanding of physicians’ beliefs and attitudes associ-
ated with prescription and continued use of BZD in
Portugal. These results should be taken in consideration
when addressing future medical educational interventions,
especially aimed at capacitating physicians to motivate
and help patients to cease BZD consumption.
Abbreviations
BZD: Benzodiazepines; DHD: Defined daily dose per 1000 persons;
KMO: Kaiser–Meyer–Olkin; OECD: Organization for Economic Co-operation
and Development; PMA: Portuguese Medical Association; PUBS: Perception
about Use of BZD Scale
Acknowledgements
The authors would like to thank the Portuguese Medical Association for their
support to this study. The authors would also like to acknowledge all
participating physicians for taking the time to complete the survey.
Neves et al. BMC Family Practice           (2019) 20:71 Page 6 of 8
Funding
Calouste Gulbenkian Foundation funded this study. The funder had no role
in the study design, data collection, data analysis, interpretation of data,
presentation of results, or decision to submit for publication.
Availability of data and materials
The data that support the findings of this study are not publically available
(as per the Portuguese Law enforcement), but summary data can be made
available upon reasonable request. Interested persons should contact the
corresponding author.
Authors’ contributions
IN. was involved in every step of the study (literature review, questionnaire
development, data collection, data analysis) and prepared the first draft of
the paper. JO. and MF. participated in questionnaire development and
manuscript revision. OS. was involved in the questionnaire development,
data analysis and manuscript revision. VM. (principal investigator) was
responsible for study design and coordination and for manuscript revision.
All authors contributed for and agreed with the final version of the paper.
Ethics approval and consent to participate
The study was approved by the Regional Health Administrations’ Ethics
Committee and authorized by the Portuguese Data Protection Authority.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Instituto de Medicina Preventiva e Saúde Pública, Faculdade de Medicina,
Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal.
2Administração Regional de Saúde de Lisboa e Vale do Tejo IP, Av. Estados
Unidos da América 77, 1700-179 Lisbon, Portugal. 3Instituto de Saúde
Ambiental, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas
Moniz, 1649-028 Lisbon, Portugal.
Received: 22 December 2018 Accepted: 16 May 2019
References
1. Osswald W, Guimarães S. Drug therapy and its pharmacological bases
[Terapêutica medicamentosa e suas bases farmacológicas]. 4th Editio. Porto
Editora; 2004. 90–107 p.
2. Ashton H. Benzodiazepines: How they work & how to withdraw
[internet]. 2002 [cited 2015 Oct 8]. Available from: http://www.benzo.
org.uk/manual/index.htm
3. Eagles L. Guidance for prescribing and withdrawal of benzodiazepines and
hipnotics in general practice [Internet]. 2008. p. 1–16. Available from: http://
www.benzo.org.uk
4. Kollen BJ, van der Veen WJ, Groenhof F, Donker GA, van der Meer K.
Discontinuation of reimbursement of benzodiazepines in the Netherlands:
does it make a difference? BMC fam Pract [internet]. BMC Fam Pract. 2012;
13(1):111 Available from: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid=3534512&tool=pmcentrez&rendertype=abstract.
5. Maria VA, Pimpão MV, Carvalho ML. Characterization of Benzodiazepine
Consumption in Primary Health Care [Caracterização do Consumo de
Benzodiazepinas em Cuidados de Saúde Primários]. Rev Port Clínica Geral.
1994;11:99–114.
6. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States.
JAMA Psychiatry [Internet] 2015;72(2):136–142. Available from: https://www.
ncbi.nlm.nih.gov/pubmed/25517224.
7. Cunningham CM, Hanley GE, Morgan S. Patterns in the use of
benzodiazepines in British Columbia: Examining the impact of increasing
research and guideline cautions against long-term use. Health Policy (New
York) [Internet]. Elsevier Ireland Ltd; 2010;97(2–3):122–9. Available from:
https://doi.org/10.1016/j.healthpol.2010.03.008
8. Carrasco-Garrido P, Hernández-Barrera V, Jiménez-Trujillo I, Esteban-
Hernández J, Álvaro-Meca A, López-De Andrés A, et al. Time trend in
psychotropic medication use in Spain: a nationwide population-based
study. Int J Environ Res Public Health. 2016;13(12).
9. García MAF, Olry de Labry Lima A, Ferrer Lopez I, Bermúdez-Tamayo C.
Analysis of changes in trends in the consumption rates of benzodiazepines
and benzodiazepine-related drugs. J Pharm Policy Pract Journal of
Pharmaceutical Policy and Practice; 2018;11(1):1–8.
10. Furtado C. Psychopharmaceuticals: Evolution of consumption in Portugal
mainland (2000-2012) [Psicofármacos: Evolução do consumo em Portugal
Continental (2000 – 2012)]. Infarmed, IP. 2014:1–21.
11. OECD. OECD Health data: pharmaceutical market. 2017.
12. French DD, Campbell R, Spehar A, Angaran DM. Benzodiazepines and injury:
a risk adjusted model. Pharmacoepidemiol Drug Saf. 2005;14(1):17–24.
13. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, et al.
Association of road-traffic accidents with benzodiazepine use. Lancet. 1998;
352(9137):1331–6.
14. Airagnes G, Pelissolo A. Lavall??E M, Flament M, Limosin F. benzodiazepine
misuse in the elderly: risk factors, consequences, and management. Curr
psychiatry rep [internet]. Current Psychiatry Reports. 2016;18(10) Available
from: https://doi.org/10.1007/s11920-016-0727-9.
15. Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA, et al.
Benzodiazepine use and risk of incident dementia or cognitive decline:
prospective population based study. BMJ [Internet]. 2016;352(feb02_4):i90
Available from: http://www.bmj.com/content/352/bmj.i90.
16. Shash D, Kurth T, Bertrand M, Dufouil C, Barberger-Gateau P, Berr C, et al.
Benzodiazepine, psychotropic medication, and dementia: a population-
based cohort study. Alzheimers Dement. 2016;12(5):604–13.
17. Takada M, Fujimoto M, Hosomi K. Association between benzodiazepine use and
dementia: data Mining of Different Medical Databases. Int J Med Sci [Internet].
2016;13(11):825–834. Available from: http://www.medsci.org/v13p0825.htm
18. Hinrichsen A, Leipzig R. Review : supervised withdrawal plus other
interventions reduces benzodiazepine use in older persons. Am Coll
Physicians. 2014;161:2–3.
19. Vicens C, Bejarano F, Sempere E, Mateu C, Fiol F, Socias I, et al. Comparative
efficacy of two interventions to discontinue long-term benzodiazepine use:
cluster randomised controlled trial in primary care. Br J Psychiatry [Internet].
2014;204(6):471–479. Available from: https://doi.org/10.1192/bjp.bp.113.134650
20. Anthierens S, Habraken H, Petrovic M, Deveugele M, De Maeseneer J,
Christiaens T. First benzodiazepine prescriptions. Qualitative study of
patients’ perspectives. Can Fam Physician. 2007;53:1200–1.
21. Anthierens S, Habraken H, Petrovic M, Christiaens T. The lesser evil? Initiating
a benzodiazepine prescription in general practice. Scand J Prim Health Care
[Internet]. 2007;25(4):214–219. Available from: https://doi.org/10.1080/
02813430701726335
22. Cook JM, Marshall R, Masci C, Coyne JC. Physicians’ perspectives on
prescribing benzodiazepines for older adults: a qualitative study. J Gen
Intern Med. 2007;22(3):303–7.
23. Siriwardena AN, Qureshi Z, Gibson S, Collier S, Latham M. GPs’ attitudes
to benzodiazepine and “Z-drug” prescribing: a barrier to
implementation of evidence and guidance on hypnotics. Br J Gen
Pract. 2006;56(533):964–7.
24. Anthierens S, Pasteels I, Habraken H, Steinberg P, Declercq T, Christiaens T.
Barriers to nonpharmacologic treatments for stress, anxiety, and insomnia.
Family physicians’ attitudes toward benzodiazepine prescribing. Can Fam
Physician. 2010;56:398–406.
25. Cottraux J. Nonpharmacological treatments for anxiety disorders. Dialogues
Clin Neurosci. 2002;4(3):305–19.
26. Vyas KU. Non-pharmacological management of insomnia. Br J Med Pract.
2013;6(3):6–10.
27. Maria VA. Benzodiazepine chronic use: the responsibility of the family
physician.[Consumo Crónico de Benzodiazepinas: a responsabilidade do
Médico de Família.]. Rev Port Clínica Geral. 1994;11:91–2.
28. Janeiro MS. Benzodiazepine prescription in a primary health care unit of the
Baixo Alentejo region [Prescrição de benzodiazepinas numa extensão rural
do Baixo Alentejo]. Rev Port Clínica Geral. 2000;16:361–77.
29. Sirdifield C, Anthierens S, Creupelandt H, Chipchase SY, Christiaens T,
Siriwardena AN. General practitioners’ experiences and perceptions of
Neves et al. BMC Family Practice           (2019) 20:71 Page 7 of 8
benzodiazepine prescribing: systematic review and meta-synthesis. BMC
Fam Pract. 2013;14(191):2–13.
30. Bartlett MS. A note on the multiplying factors for various chi square
approximations. J R Stat Soc. 1954;16(Series B):296–8.
31. Tavakol M, Dennick R. Making sense of Cronbach ’ s alpha. Int J Med Educ.
2011;2:53–5.
32. Siriwardena AN, Apekey T, Tilling M, Dyas JV, Middleton H, Ørner R. General
practitioners’ preferences for managing insomnia and opportunities for
reducing hypnotic prescribing. J Eval Clin Pract. 2010;16(4):731–7.
33. Srisurapanont M, Garner P, Critchley J, Wongpakaran N. Benzodiazepine
prescribing behaviour and attitudes: a survey among general practitioners
practicing in northern Thailand. BMC Fam Pract. 2005;6:1–5.
34. Ajzen I, Joyce N, Sheikh S, Cote NG. Knowledge and the prediction of
behavior: the role of information accuracy in the theory of planned
behavior. Basic Appl Soc Psych. 2011;33(2):101–17.
35. Furtado C, Teixeira I. Use of Benzodiazepines in Portugal mainland (1999-
2003) [Utilização De Benzodiazepinas Em Portugal Continental (1999-2003)].
Acta Medica Port. 2006;19:239–46.
36. Almeida J miguel C. de. Portuguese National Mental Health Plan ( 2007 –
2016 ) executive summary. Ment Heal Fam Med. 2009;6:233–44.
37. Miller W, Rollnick S. Motivational interviewing: helping people change. 2nd
ed. New York: The Guilford Press; 2002.
38. Loscertales HR, Wentzky V, Dursteler K, Strasser J, Hersberger KE, Arnet I.
Successful withdrawal from high-dose benzodiazepine in a young patient
through electronic monitoring of polypharmacy: a case report in an
ambulatory setting. Ther Adv Psychopharmacol. 2017;7(5):181–7.
39. Ordem dos Médicos. Ordem dos Médicos - Estatísticas Nacionais [Internet].
2017 [cited 2019 Apr 2]. Available from: https://ordemdosmedicos.pt/
estatisticas-nacionais/#1505070622822-9e31b1b1-6d1a.
Neves et al. BMC Family Practice           (2019) 20:71 Page 8 of 8
